Zydus Cadila gets USFDA’s approval for Lansoprazole DR Capsules

21 Aug 2013 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Lansoprazole DR Capsules in different strengths of 15mg and 30mg. The drug falls in the anti-ulcerant segment. The estimated sales in 2012 as per IMS for Lansoprazole DR Capsules were $501 million.

The group has now 81 approvals and has so far filed 186 ANDAs since the commencement of filing process in FY2003-04.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

 

Zydus Lifesciences Share Price

971.15 -2.75 (-0.28%)
23-Dec-2024 14:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1817.50
Dr. Reddys Lab 1336.30
Cipla 1474.25
Lupin 2159.70
Zydus Lifesciences 971.15
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.